<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A few weeks after treatment with INH, <z:chebi fb="2" ids="28077">RFP</z:chebi> and SM, severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> developed in a 49-year-old man with pulmonary atypical <z:e sem="disease" ids="C0026918" disease_type="Disease or Syndrome" abbrv="">mycobacteriosis</z:e> due to M. kansasii </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> drugs were discontinued immediately after bone marrow examination revealed severely <z:e sem="disease" ids="C0151773" disease_type="Disease or Syndrome" abbrv="">hypoplastic marrow</z:e>, but <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> continued for several months </plain></SENT>
<SENT sid="2" pm="."><plain>Although M. kansasii was sensitive to other drugs including CS and TH, these two drugs were also discontinued because of their respective psychiatric and hepatic adverse effects </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="7731">Ofloxacin</z:chebi> (<z:chebi fb="0" ids="7731">OFLX</z:chebi>), to which M. kansasii was sensitive, was administered without clinical improvement and complete resistance to <z:chebi fb="0" ids="7731">OFLX</z:chebi> developed after several months treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Right upper and middle lobectomy and S6 partial lobectomy was performed, and postoperative <z:chebi fb="0" ids="9212">sparfloxacin</z:chebi> (SPFX) administration resulted in cure of the disease </plain></SENT>
<SENT sid="5" pm="."><plain>Drug sensitivity testing revealed that the organism had acquired resistance to <z:chebi fb="0" ids="7731">OFLX</z:chebi>, but was still sensitive to SPFX </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, SPFX appears to be an useful drug for the treatment of atypical <z:e sem="disease" ids="C0026918" disease_type="Disease or Syndrome" abbrv="">mycobacteriosis</z:e> </plain></SENT>
</text></document>